SINO BIOPHARM (01177.HK) -0.030 (-0.472%) Short selling $142.91M; Ratio 75.915% announced its 2025 annual results, reporting revenue of RMB31.834 billion, up 10.3% YoY. Profit attributable to shareholders was RMB2.343 billion, down 33% YoY, with an EPS of RMB13.02 cents.
AASTOCKS Financial News